AZD-0466 is under development for the treatment of acute myeloid leukemia, relapsed/refractory (R/R) mantle cell lymphoma (MCL), R/R follicular lymphoma (FL) or marginal zone lymphoma (MZL) including splenic, nodal, and extranodal subtypes and R/R diffuse large B-cell lymphoma (DLBCL), multiple myeloma, myelodysplastic syndrome, B-cell acute lymphoblastic leukemia and acute myeloid leukemia. It is developed based on dendrimer drug delivery technology and DEP technology . It acts by targeting Bcl2/xL protein. The drug candidate is administered through intravenous route as a nanoparticle formulation. It is a new molecular entity (NME). It was under development for the treatment of colorectal, pancreatic, bladder, anal urtheral, bile duct cancer, acute lymphocytic leukemia, lymphoma, relapsed and refractory acute myeloid leukemia, myelodysplastic syndrome, solid tumor, small-cell lung cancer, chronic myelomonocytic leukemia (CMML), multiple myeloma (Kahler Disease)
Potential revenue stream to Starpharma over life of drug
$2.4 billion
Our current market cap is around $160 million
The above drug alone, if successful through clinical trials would generate revenue equivalent to 15 x current market cap of Starpharma
And that is just one drug
SPL Price at posting:
39.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)